Comparison of 13-, 15- and 20-valent pneumococcal conjugate vaccines in the paediatric Canadian population: A cost-utility analysis
Both Pneu-C-15 and Pneu-C-20 are expected to increase QALYs in Canadian children compared to Pneu-C-13 and may be cost-effective interventions.
Authors
- Aleksandra Wierzbowski
- Alison E. Simmons (ORCID: https://orcid.org/0000-0001-8780-9467)
- Gebremedhin Beedemariam Gebretekle (ORCID: https://orcid.org/0000-0002-2485-505X)
- Matthew Tunis (ORCID: https://orcid.org/0000-0003-2092-9143)
- Robert Pless (ORCID: https://orcid.org/0000-0001-5775-8216)
- Ashleigh R. Tuite (ORCID: https://orcid.org/0000-0002-4373-9337)
Institutions
- 3M (United States) (US)
- Public Health Agency of Canada (CA)
- University of Toronto (CA)
Publication Details
- Journal
- Canada Communicable Disease Report
- Published
- 2025-02-12
- DOI
- https://doi.org/10.14745/ccdr.v51i23a02
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00